Moffitt Cancer Center researchers identify hidden target of ROS1 inhibitor lorlatinib
Targeted cancer drugs are widely used because of their ability to inhibit specific proteins involved in cancer development with fewer side effects compared to chemotherapy drugs.
Danielle Ellis Uwe Rix Department Of Defense Lung Cancer Research Program Department Of Drug Discovery At Moffitt National Cancer Institute Moffitt Lung Cancer Center
Source: news-medical.net